Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q1 EPS of ($0.74), $0.07 worse than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
• Home Depot (HD) Reiterated at Hold by Stifel as Survey Provides Positive Results
• Scotts Miracle-Gro (SMG) Reiterated at Buy by Stifel on Strengthening Lawn, Garden Trends